Skin Cancer

Skin cancer at the BVA tells a counterintuitive story. Most veterans filing skin cancer claims assume the Agent Orange presumption covers them, they were exposed to herbicides, herbicides cause cancer, therefore the cancer is presumed service-connected. That logic is intuitive and partially right. But it doesn't fit how 38 CFR § 3.309(e) actually reads.

The herbicide presumption in 38 USC § 1116 and 38 CFR § 3.309(e) covers specific diseases. Notably absent from both disease lists are basal cell carcinoma, cutaneous squamous cell carcinoma, and melanoma. Melanoma does have a separate toxic-exposure presumption under 38 USC §§ 1119 and 1120 for a covered veteran, but that is not an Agent Orange presumption.

In our analysis of 569 BVA skin cancer cases, the presumptive lane grants at 32 percent while the direct lane grants at 42 percent, an inversion of the usual pattern. The reason is that when veterans file under a presumption that doesn't actually apply, the Board has to deny the presumptive theory even when the underlying condition is real and clearly related to sun exposure during service. The direct lane, by contrast, can succeed when the medical evidence establishes that in-service sun exposure (combined sometimes with other carcinogenic exposures) caused the eventual skin cancer.

TL;DR

• 569 skin cancer cases in our BVA dataset. Outcomes: 35.1% granted, 31.3% denied, 33.6% remanded. The remand rate is unusually high. Most skin cancer claims need additional development before final decision.
• Skin cancer rates under several diagnostic codes depending on type and treatment. DC 7818 covers malignant skin neoplasms generally (excluding melanoma); DC 7833 covers melanoma. The 100% treatment rating applies only when therapy is comparable to treatment for a systemic malignancy. Treatment confined to the skin does not receive that automatic 100%.
• The Agent Orange presumption does not cover basal cell carcinoma, squamous cell carcinoma, or melanoma. It covers only specific named cancers under 38 CFR § 3.309(e). Veterans filing skin cancer claims under the herbicide presumption usually fail on the presumptive theory.
• Sun exposure during service is the medically supported direct nexus theory for most skin cancers. Veterans with documented outdoor service (infantry, aviation, naval surface, certain MOS categories) can establish direct service connection when the nexus opinion engages with the cumulative UV exposure framework.
• Strong nexus opinions grant at 96.9%. Weak nexus grants at 0%. The opinion-quality cliff is steep, and the weak-nexus failure pattern is often veterans trying to use the wrong legal theory.
• The modal granted rating is 30 percent (14 cases) and 100 percent (11 cases). Many veterans land at 0 percent after treatment because skin cancer residuals (scarring) don't always clear the rating thresholds.

Which Diagnostic Codes Apply

Skin cancer ratings depend on which type of skin cancer and which body areas are involved. The framework lives in 38 CFR § 4.118 (the skin chapter):

DC 7818. Malignant skin neoplasms (other than malignant melanoma)

This is the catch-all for basal cell carcinoma, squamous cell carcinoma, and other non-melanoma skin cancers. The structure is:

• Ordinarily rate disfigurement, scars, or functional impairment.
• 100% only when treatment is comparable to therapy for a systemic malignancy, such as systemic chemotherapy, X-ray therapy more extensive than the skin, or surgery more extensive than wide local excision.
• When that 100% rule applies, a mandatory examination follows six months after treatment ends; if there is no recurrence or metastasis, rate the residuals.
• If treatment is confined to the skin, the 100% treatment rule does not apply.

DC 7833. Malignant melanoma

DC 7833 uses the same distinction as DC 7818: rate scars, disfigurement, or functional impairment unless the melanoma requires therapy comparable to treatment for a systemic malignancy. Only that systemic-level therapy triggers the 100 percent rating and six-month re-evaluation rule. Treatment confined to the skin does not.

DC 7800. Burn scars, scars due to other causes, or other disfigurement of the head, face, or neck

This is where many post-treatment skin cancer ratings land. The criteria turn on the number and severity of disfiguring characteristics: scar width and length, hyperpigmentation, hypopigmentation, abnormal skin texture, missing underlying soft tissue, induration and inflexibility.

• 10%: One characteristic of disfigurement
• 30%: Visible or palpable tissue loss and either gross distortion or asymmetry of one feature, OR two or three characteristics of disfigurement
• 50%: Visible or palpable tissue loss and either gross distortion or asymmetry of two features, OR four or five characteristics of disfigurement
• 80%: Visible or palpable tissue loss and either gross distortion or asymmetry of three or more features, OR six or more characteristics of disfigurement

DC 7801-7805. Scars not of the head, face, or neck

The ladder runs from 10 to 40 percent based on area, depth, and whether the scar is deep, nonlinear, or painful/unstable. Most skin cancer scars on the body rate at 10 or 0 percent unless they're particularly large or symptomatic.

Why the Agent Orange Presumption Doesn't Cover Most Skin Cancers

The herbicide disease lists in 38 USC § 1116 and 38 CFR § 3.309(e) are specific, not open-ended cancer categories. They include cancers such as:

• Chronic B-cell leukemias
• Hodgkin's disease
• Multiple myeloma
• Non-Hodgkin's lymphoma
• Prostate cancer
• Respiratory cancers (lung, larynx, trachea, and bronchus)
• Soft-tissue sarcomas (other than osteosarcoma, chondrosarcoma, Kaposi's sarcoma, and mesothelioma)

Notably absent from the herbicide presumption: basal cell carcinoma, cutaneous squamous cell carcinoma, and melanoma. The statute and regulation do not presume those diseases based on herbicide exposure.

This creates a recurring failure pattern in our dataset. A Vietnam-era veteran files a claim for basal cell carcinoma asserting Agent Orange presumption. The C&P examiner notes the cancer type. The rating decision denies the presumption because the cancer isn't listed. The veteran appeals. The Board affirms the denial on the presumption theory but sometimes remands or grants on the direct theory if the medical evidence supports cumulative sun exposure during service.

The 32 percent presumptive grant rate reflects this pattern. Many presumptive-coded skin cancer cases fail on the theory but succeed when the case pivots to direct service connection based on sun exposure.

The Sun Exposure Direct Theory

The medically supported direct service connection theory for most skin cancers is cumulative UV exposure. Skin cancer risk correlates strongly with lifetime sun exposure, and the medical literature supports the framework that high-exposure service (outdoor work in tropical or desert environments, naval surface duty in equatorial waters, aviation operations at altitude, infantry operations in sunny terrain) significantly contributes to later skin cancer development.

For veterans pursuing the direct theory, the nexus opinion has to do specific work:

• Establish the cumulative UV exposure during service
• Establish that the exposure was significant enough to be a substantial contributing factor
• Address competing post-service exposures (occupational outdoor work, recreational sun exposure)
• Connect the exposure to the specific cancer type and location

The strongest direct-lane cases have veterans with documented outdoor MOS categories, infantry in tropical or desert deployments, aviation, naval surface, construction battalions, military police with extensive outdoor patrol. The location of the cancer on the body matters too. Cancers on the head, face, neck, ears, forearms, and back of the hands are anatomically consistent with sun exposure. Cancers on areas not typically sun-exposed (chest, abdomen, back, lower extremities) are harder to attribute to UV exposure alone.

In our dataset, the direct lane grants at 42.1 percent, above the presumptive lane's 32 percent. The reason is that direct-lane cases that win are typically well-developed on the sun exposure theory, while presumptive-lane cases often fail because they're trying to invoke a presumption that doesn't cover the cancer type.

PACT Act: Melanoma Is Listed, Most Skin Cancers Are Not

The PACT Act's broad disease authority is 38 USC § 1120, applied to a covered veteran under § 1119. Section 1120 expressly lists melanoma. It does not list basal cell carcinoma or generic cutaneous squamous cell carcinoma.

Section 3.320 does not supply a generic skin-cancer presumption either. Its squamous-cell entries are squamous cell carcinoma of the larynx and trachea, not skin. Covered toxic exposure may still support direct service connection for a nonlisted skin cancer and may trigger development under 38 USC § 1168, but exposure alone is not the disease nexus.

In our dataset, 41 of 153 presumptive-category skin cancer cases invoke burn-pit or PACT Act exposure. That coding reflects the theory discussed in the decision; it does not mean every skin cancer in those cases was legally presumptive.

Camp Lejeune and Radiation Lanes

Camp Lejeune contaminated water: The disability presumption uses the qualifying-service rule in 38 CFR § 3.307(a)(7) and the disease list in § 3.309(f). That list does not include basal cell carcinoma, cutaneous squamous cell carcinoma, or melanoma. A Camp Lejeune exposure theory for skin cancer therefore needs a direct nexus; a separate presumptive disease supports a secondary claim only when medical evidence actually connects the two conditions.

Radiation exposure (38 CFR § 3.311): Skin cancer is listed as a radiogenic disease, but § 3.311 is a dose-development and adjudication procedure, not an automatic service-connection presumption. Skin cancer is not one of the diseases named in the separate radiation presumption at § 3.309(d).

When the Six-Month Re-Evaluation Rule Applies

The six-month re-evaluation rule applies only when DC 7818 or DC 7833 first authorizes 100 percent because treatment is comparable to therapy for a systemic malignancy. When treatment is confined to the skin, that automatic 100 percent and six-month sequence does not apply. After qualifying systemic-level treatment, the post-treatment rating depends on recurrence, metastasis, and residuals.

For most basal cell carcinomas and squamous cell carcinomas treated with Mohs surgery or simple excision, the residual is a small scar. These scars often don't clear the rating thresholds under DC 7800-7805, and many veterans end up at 0 percent post-treatment. The 30 percent and 100 percent post-treatment ratings in our dataset usually involve veterans with multiple cancers, large excision sites with significant disfigurement, or melanoma with metastatic disease that re-triggers the active-treatment 100 percent rating.

The rating math at the post-treatment stage depends heavily on which body area was treated. Head, face, and neck scars (DC 7800) rate higher than scars elsewhere because the disfigurement criteria are more developed. A small basal cell carcinoma scar on the nose can clear a 30 percent rating under DC 7800; the same size scar on the forearm might rate 0 percent under DC 7805.

Bottom Line

Skin cancer is rated under several diagnostic codes in 38 CFR § 4.118. DC 7818 covers non-melanoma skin cancers and DC 7833 covers melanoma. Both ordinarily rate scars, disfigurement, or functional impairment; 100 percent applies only when therapy is comparable to treatment for a systemic malignancy, and treatment confined to the skin does not qualify. The Agent Orange presumption does not cover basal cell carcinoma, cutaneous squamous cell carcinoma, or melanoma. For a covered veteran, 38 USC §§ 1119 and 1120 separately presume melanoma, but not basal cell carcinoma or generic cutaneous squamous cell carcinoma. Section 3.320's squamous-cell cancers are limited to the larynx and trachea. Most other skin-cancer claims require direct nexus evidence, such as a medically supported in-service UV or toxic-exposure theory.

Methodology and Limitations

• Data source: 38 CFR § 4.118 DC 7800 through DC 7833 (skin chapter), 38 USC § 1116 and 38 CFR § 3.309(e) (herbicide presumption), 38 USC §§ 1119 and 1120 (melanoma toxic-exposure presumption), 38 USC § 1168 (toxic-exposure examinations and opinions), 38 CFR §§ 3.307(a)(7) and 3.309(f) (Camp Lejeune), 38 CFR §§ 3.309(d) and 3.311 (radiation), and Claim Raven's analysis of BVA decisions tagged with skin cancer as the primary condition.
• Sample size: 569 BVA decisions involving skin cancer as the primary condition. Outcomes split granted 35.1% (200), denied 31.3% (178), remanded 33.6% (191). Connection-type, nexus-quality, denial-reason, and rating-tier breakdowns are coded from the Board's discussion in each decision.
• Limitations: Presumptions apply only to diseases named in the controlling statute or regulation, including valid later additions. Veterans and the Board sometimes treat broader exposure-based theories under presumptive coding even when the specific cancer isn't on the named list; our coding reflects how the Board treated the case rather than whether the presumption legally applied. Sun exposure as a direct nexus theory is medically well-supported but the Board has been inconsistent about accepting it without specific service-record documentation. The post-treatment residuals rating depends on which body area and severity; the rating-tier distribution in our data reflects the cases where a tier was specifically discussed. These observations describe BVA patterns and are not predictions of individual outcomes, and Claim Raven is data analysis, not legal, medical, or VA-accredited advice.